雷公藤多苷联合托法替布治疗难治性类风湿关节炎的探索
Exploration of Tripterygium Glycosides Combined with Tofacitinib in Refractory Rheumatoid Arthritis
DOI: 10.12677/TCM.2023.1210440, PDF,  被引量   
作者: 覃会蓉, 沈小兰：三峡大学第一临床医学院，宜昌市中心人民医院，风湿免疫科，湖北 宜昌；三峡大学健康医学院，湖北 宜昌；向 高：三峡大学第一临床医学院，宜昌市中心人民医院，风湿免疫科，湖北 宜昌；侯晓强*：三峡大学第一临床医学院，宜昌市中心人民医院，风湿免疫科，湖北 宜昌；三峡大学第一临床医学院风湿免疫病研究所，湖北 宜昌
关键词: 类风湿关节炎(RA)；难治性类风湿关节炎(RRA)；中医；雷公藤多苷；托法替布；Rheumatoid Arthritis (RA)； Refractory Rheumatoid Arthritis (RRA)； Traditional Chinese Medicine (TCM)； Tripterygium Glycosides； Tofacitinib
摘要: 类风湿关节炎(rheumatoid arthritis, RA)是一种慢性自身免疫性疾病，主要表现为关节滑膜部位的炎症及具有破坏性对称性的关节病变。早期诊断、早期治疗、尽快控制病情变化有利于防止关节畸形，减轻患者身心压力，提高患者生活质量。因此，RA一经确诊，应尽早治疗。传统合成抗风湿药物(conventional synthesis disease-modifying anti-rheumatic drugs, csDMARDS)是治疗RA的常用药物，并且取得了较好的临床疗效，但仍然有少部分RA患者经过csDMARDs治疗后，病情不能缓解或者无应答，临床上称之为难治性类风湿性关节炎(Refractory rheumatoid arthritis, RRA)。RRA是临床治疗的难点，本文对目前的治疗进展以及治疗趋势进行综述，以期为RRA的临床治疗提供参考。
Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune disease, mainly manifested as inflammation of synovial joints and destructive symmetrical joint lesions. Early diagnosis, early treatment, and con-trol of the disease as soon as possible can help prevent joint deformity, reduce physical and mental stress, and improve the quality of life of patients. Therefore, once RA is diagnosed, it should be treated as early as possible. Conventional synthesis disease-modifying anti-rheumatic drugs (csDMARDS) are commonly used in the treatment of RA and have achieved good clinical efficacy, but there are still a small number of RA patients who cannot be relieved or have no response after treatment with csDMARDs, which is clinically known as refractory rheumatoid arthritis (RRA). RRA is a difficult problem in clinical treatment. This paper reviews the current treatment progress and treatment trend in order to provide reference for the clinical treatment of RRA.
文章引用：覃会蓉, 向高, 沈小兰, 侯晓强. 雷公藤多苷联合托法替布治疗难治性类风湿关节炎的探索[J]. 中医学, 2023, 12(10): 2929-2935. https://doi.org/10.12677/TCM.2023.1210440

参考文献

[1] Silvagni, E., Giollo, A., Sakellariou, G., et al. (2020) One Year in Review 2020: Novelties in the Treatment of Rheuma-toid Arthritis. Clinical and Experimental Rheumatology, 38, 181-194. [Google Scholar] [CrossRef] [PubMed]
[2] Philippou, E., Petersson, S.D., Rodomar, C. and Ni-kiphorou, E. (2021) Rheumatoid Arthritis and Dietary Interventions: Systematic Review of Clinical Trials. Nutrition Re-views, 79, 410-428. [Google Scholar] [CrossRef] [PubMed]
[3] 孙宇迪, 李顾佳, 季彤, 等. 新型托法替布的研究进展[J]. 山东化工, 2023, 52(1): 68-70.
[4] Zuo, J., Ji, C.L., Olatunji, O.J., et al. (2020) Bioactive Fractions from Securidaca inappendiculata Alleviated Collagen-Induced Arthritis in Rats by Regulating Metabolism-Related Signaling. The Kaohsiung Journal of Medical Sciences, 36, 523-534. [Google Scholar] [CrossRef] [PubMed]
[5] Jin, S., Li, M., Fang, Y., et al. (2017) Chinese Registry of Rheumatoid Arthritis (CREDIT): II. Prevalence and Risk Factors of Major Comorbidities in Chinese Patients with Rheumatoid Arthritis. Arthritis Research & Therapy, 19, Article No. 251. [Google Scholar] [CrossRef] [PubMed]
[6] 周云杉, 王秀茹, 安媛, 等. 全国多中心类风湿关节炎患者残疾及功能受限情况的调查[J]. 中华风湿病学杂志, 2013, 17(8): 526-532.
[7] 罗寰, 张霞, 冯娅娆, 等. 托法替布与益赛普分别联合甲氨蝶呤治疗难治性类风湿关节炎的疗效及安全性分析[J]. 天津医药, 2022, 50(8): 883-887.
[8] de Hair, M., Jacobs, J., Schoneveld, J., et al. (2018) Difficult-to-Treat Rheumatoid Arthritis: An Area of Unmet Clinical Need. Rheumatology, 57, 1135-1144.
[9] Buch, M.H. (2018) Defining Refractory Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 77, 966-969. [Google Scholar] [CrossRef] [PubMed]
[10] Kearsley-Fleet, L., Davies, R., De Cock, D., et al. (2018) Biologic Refractory Disease in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Reg-ister for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 77, 1405-1412. [Google Scholar] [CrossRef] [PubMed]
[11] Nagy, G., Roodenrijs, N., Welsing, P., et al. (2022) EULAR Points to Consider for the Management of Difficult-to-Treat Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 81, 20-33. [Google Scholar] [CrossRef] [PubMed]
[12] Smolen, J.S., Aletaha, D., Bijlsma, J.W., et al. (2010) Treating Rheumatoid Arthritis to Target: Recommendations of an International Task Force. Annals of the Rheumatic Dis-eases, 69, 631-637. [Google Scholar] [CrossRef] [PubMed]
[13] 徐辉, 邓玲, 李学荣. 托珠单抗治疗活动性难治性类风湿关节炎的疗效及不良反应[J]. 中国医刊, 2019, 54(4): 425-427.
[14] 谢文慧, 张卓莉. 类风湿关节炎早期缓解率及其影响因素的研究[J]. 中华风湿病学杂志, 2019, 23(1): 25-30.
[15] 李宏超, 徐丽玲, 苏茵. 难治性类风湿关节炎诊治探讨[J]. 中华风湿病学杂志, 2019, 23(10): 689-693.
[16] Smolen, J.S., Landewé, R.B.M., Bijls-ma, J.W.J., et al. (2020) EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Bi-ological Disease-Modifying Antirheumatic Drugs: 2019 Update. Annals of the Rheumatic Diseases, 79, 685-699. [Google Scholar] [CrossRef] [PubMed]
[17] Nagy, G., Roodenrijs, N.M., Welsing, P.M., et al. (2020) EULAR Definition of Difficult-to-Treat Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 80, 31-35. [Google Scholar] [CrossRef] [PubMed]
[18] 王志强, 宫彩霞, 张晓刚, 等. 雷公藤多苷不同时间给药联合甲氨蝶呤治疗难治性类风湿关节炎疗效观察[J]. 现代中西医结合杂志, 2020, 29(1): 11-14, 54.
[19] 谢李, 邹庆华, 石颖, 等. 艾拉莫德联合MTX对难治性类风湿关节炎患者IL-1、血清TNF-α、VEGF水平的影响[J]. 贵州医药, 2018, 42(7): 831-832.
[20] 周涛, 许超平, 肖颖, 等. 药物联合血浆置换治疗难治性类风湿关节炎的临床观察[J]. 临床内科杂志, 2019, 36(10): 689-692.
[21] 邢继尧, 魏林苇. 关节镜下滑膜全切除术治疗肘关节类风湿关节炎的研究进展[J]. 中国微创外科杂志, 2019, 19(4): 350-354.
[22] 李习军. 膝关节类风湿性关节炎患者采用关节镜下滑膜切除术治疗的疗效研究[J]. 临床医药文献电子杂志, 2016, 3(22): 4363, 4366.
[23] 居艳娟, 郭迪斌, 陈琥, 等. 甲氨蝶呤与艾拉莫德治疗难治性类风湿关节炎的临床疗效评价[J]. 中国现代医生, 2020, 58(8): 106-109.
[24] 韩琦, 刘健, 方妍妍, 等. 中医药降低类风湿关节炎患者再发入院的风险——基于人群的数据挖掘及回顾性队列研究[J]. 风湿病与关节炎, 2023, 12(8): 8-13.
[25] 李津津. 白芍总苷胶囊联合泼尼松治疗类风湿关节炎的临床研究[J]. 现代药物与临床, 2020, 35(4): 748-751.
[26] 陈士军, 朱卫民, 田培军. 小剂量雷公藤总苷联合甲氨蝶呤对类风湿关节炎患者临床症状、炎性因子及关节功能的影响[J]. 临床误诊误治, 2020, 33(3): 52-56.
[27] 朱琳, 陈鹏, 邹荥, 等. 甲氨蝶呤联合雷公藤多苷片治疗老年类风湿关节炎的临床疗效及随访分析[J]. 世界中西医结合杂志, 2020, 15(2): 339-347.
[28] 刘莉, 闫君, 舒积成, 等. 雷公藤生物碱类成分及其药理活性研究进展[J]. 天然产物研究与开发, 2019, 31(12): 2170-2181.
[29] 谢立虎. 雷公藤多苷在类风湿性关节炎治疗中的价值分析及对VEGF、VEGFR2表达水平的影响[J]. 医学理论与实践, 2019, 32(14): 2207-2209.
[30] 王靖霞, 刘春芳, 李逸群, 等. 雷公藤多苷片抑制实验性类风湿关节炎血管新生的作用研究[J]. 中国中药杂志, 2019, 44(16): 3441-3447.
[31] 刘巍, 张艳艳. 雷公藤多苷对类风湿关节炎患者成纤维样滑膜细胞α7nAChR及炎症因子的作用[J]. 山东中医杂志, 2019, 38(12):1166-1170, 1197.
[32] 廖子鸿, 周志华, 戴冠东. 甲氨蝶呤加用雷公藤多甙片治疗类风湿性关节炎的临床效果探析[J]. 中国生化药物杂志, 2016, 36(5): 136-138.
[33] 王萍. 雷公藤联合甲氨蝶呤治疗类风湿性关节炎的效果比较[J]. 中国医药指南, 2019, 17(5): 2-3.
[34] Wang, X., Zu, Y., Huang, L., et al. (2017) Treatment of Rheumatoid Arthritis with Combination of Methotrexate and Tripterygium wilfordii: A Meta-Analysis. Life Sciences, 171, 45-50. [Google Scholar] [CrossRef] [PubMed]
[35] 杜寅俊, 张章, 杨甜梦, 等. 雷公藤多苷联合甲氨蝶呤对难治性类风湿关节炎患者骨代谢的影响[J]. 现代实用医学, 2021, 33(6): 768-769.
[36] 王泽凤, 霍光强, 王一丹, 等. 雷公藤多苷联合来氟米特治疗类风湿性关节炎疗效观察[J]. 实用中医药杂志, 2021, 37(1): 53-54.
[37] 中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 临床医学研究与实践, 2018, 3(12): 201.
[38] Smolen, J.S., Landewe, R., Bijlsma, J., et al. (2017) EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2016 Update. Annals of the Rheumatic Diseases, 76, 960-977. [Google Scholar] [CrossRef] [PubMed]
[39] Fraenkel, L., Bathon, J.M., England, B.R., et al. (2021) 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology, 73, 1108-1123. [Google Scholar] [CrossRef] [PubMed]
[40] 潘楠楠, 李凤菊, 菅夏楠. 托法替布与依那西普分别联合甲氨蝶呤治疗活动性类风湿关节炎的疗效及安全性[J]. 临床医学, 2023, 43(8): 105-107.
[41] 王丹, 张薇, 鲍蕴琦, 等. 枸橼酸托法替布片对不同性别中重度类风湿关节炎患者的疗效评价[J]. 检验医学与临床, 2021, 18(24): 3607-3609.
[42] 姚婷, 何欣, 青玉凤. 托法替布在类风湿关节炎治疗中的临床研究进展[J]. 临床医学进展, 2021, 11(11): 5009-5016.
[43] Simon, L.S., Taylor, P.C., Choy, E.H., et al. (2021) The Jak/STAT Pathway: A Fo-cus on Pain in Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism, 51, 278-284. [Google Scholar] [CrossRef] [PubMed]
[44] Moura, R.A. and Fonseca, J.E. (2020) JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis. Frontiers of Medicine, 7, Article 607725. [Google Scholar] [CrossRef] [PubMed]
[45] Angelini, J., Talotta, R., Roncato, R., et al. (2020) JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules, 10, Arti-cle 1002. [Google Scholar] [CrossRef] [PubMed]
[46] Wollenhaupt, J., Lee, E.B., Curtis, J.R., et al. (2019) Safety and Efficacy of Tofacitinib for up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study. Arthritis Research & Therapy, 21, Article No. 89. [Google Scholar] [CrossRef] [PubMed]
[47] 张春燕, 范小冬, 秦元, 等. JAK抑制剂托法替布治疗类风湿性关节炎效果的Meta分析[J]. 第三军医大学学报, 2018, 40(6): 543-550.
[48] 张振山, 杨磊, 朱丽娟. 托法替布治疗老年人中重度类风湿性关节炎疗效及安全性评价[J]. 深圳中西医结合杂志, 2023, 33(2): 97-99.
[49] 庞琳烜, 朱平, 李治琴, 等. 托法替布联合柳氮磺吡啶治疗类风湿关节炎的临床研究[J]. 现代药物与临床, 2022, 37(11): 2574-2577.
[50] 郑江霞, 张细凤, 刘圣徽, 等. 甲氨蝶呤联合托法替布治疗难治性类风湿关节炎的效果及对anti-CCP、IL-6的影响[J]. 中国医学创新, 2022, 19(14): 48-52.
[51] 李荣平, 陈琥, 谷晓晶, 等. 托法替布治疗难治性类风湿关节炎的临床研究[J]. 药品评价, 2021, 18(7): 428-430.
[52] 田继男. 托法替布+甲氨蝶呤治疗难治性类风湿关节炎患者的临床效果及安全性研究[J]. 当代医学, 2022, 28(7): 161-163.
[53] 程书华. 类风湿性关节炎是怎么发生的[J]. 食品与健康, 2023, 35(7): 26-27.
[54] 李良, 孙银娣, 李亚峰, 等. 四妙二藤汤联合双氯芬酸钠对类风湿关节炎患者关节情况、炎症指标和复发率的影响[J]. 陕西中医, 2019, 40(10): 1397-1399.
[55] Malemud, C.J. (2018) The Role of the JAK/STAT Signal Pathway in Rheumatoid Arthritis. Therapeutic Advances in Musculoskel-etal Disease, 10, 117-127. [Google Scholar] [CrossRef] 
[56] Ciobanu, D.A., Poenariu, I.S., Crin-gus, L.I., et al. (2020) JAK/STAT Pathway in Pathology of Rheumatoid Arthritis (Review). Experimental and Thera-peutic Medicine, 20, 3498-3503. [Google Scholar] [CrossRef] [PubMed]